As previously reported, SunTrust upgraded Amedisys to Buy from Neutral and increased its price target to $36 from $31. The firm believes the home health sector is extremely well positioned and applauds Amedisys' recent decision to abandon its AMS3 system and transition to Homecare Homebase. SunTrust said the transition will ultimately decrease both capex and IT spend and improve clinician capacity. In addition, the firm's analyst said Amedisys has added management talent and views the strong balance sheet and robust free cash flow as unappreciated.